'Pancreatic Cancer Deaths IncreasingThese recent treatment advances are long overdue. Although deaths from most malignancies are declining, pancreatic cancer moved from the fourth leading cause of cancer death to the third in 2016, surpassing breast cancer. The population is growing older and living longer, and innovative new therapies have largely passed this tumor by, Dr. Tempero said. The vast majority of patients with pancreatic cancer are diagnosed with advanced unresectable disease; most patients experience relapse after treatment. Furthermore, the “cure rate” for this disease is only 9%, and without treatment, the median survival of patients with metastatic disease is only 3 months.“This is a very tough disease,” Dr. Tempero noted. “There are no early symptoms, the tumor invades and metastasizes early, it is somewhat chemotherapy-resistant, and patients suffer from debilitating cytokine-mediated symptoms.' https://jnccn.org/view/journals/jnccn/17/5.5/article-p603.xml
OSL Price at posting:
14.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)